← All trials
NCT06464991
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 27, 2024
- Primary completion
- Aug 31, 2027
- Completion date
- Dec 31, 2030
- First posted
- Jun 18, 2024
- Last posted
- Jun 18, 2024
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IASO Pharma Inc.Lead sponsor
- Chinese Academy of Medical SciencesOfficial
- Zhejiang UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.